New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 3, 2016
09:19 EDTMRKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
09:05 EDTMRKMerck says don't read into discounting strategy based on pricing of hep C drug
Subscribe for More Information
08:54 EDTMRKMerck Chairman says industry must price products consistent with value provided
Subscribe for More Information
08:43 EDTMRKMerck says main focus of deals to be augmenting pipeline
Subscribe for More Information
08:36 EDTMRKMerck says looking for M&A, partnership opportunities in oncology, other areas
Merck executives said on the company's Q4 earnings call that they "have paid attention to what's happened in the marketplace" and are working "very actively" to reach the right kind of deals, whether they are M&A or partnerships. The executives said they are "very focused" on value creating opportunities and active in looking for opportunities in oncology and other therapeutic areas where they can build the company's pipeline.
08:17 EDTMRKMerck sees growing Januvia franchise in 2016 ex-exchange
Merck said it expects to grow the Januvia franchise in 2016 ex-exchange despite increased pricing pressure. The company said it has maintained a high market share of about 75% in the U.S. and 65% globally. Merck said that, while still early, customer feedback is very positive on Bridion. Merck said it believes its pricing strategy for hepatitis C treatment Zapatier will "maximize revenue and market share" as well as broaden and accelerate patient access. Comments from Merck's Q4 earnings conference call.
06:48 EDTMRKMerck sees FY16 non-GAAP marketing and administrative expenses below 2015 levels
Subscribe for More Information
06:48 EDTMRKMerck reports Q4 Animal Health sales $830M
06:47 EDTMRKMerck reports Q4 Januvia/Janumet sales $1.45B
Subscribe for More Information
06:46 EDTMRKMerck sees FY16 non-GAAP EPS $3.60-$3.75, consensus $3.72
Subscribe for More Information
06:46 EDTMRKMerck reports Q4 non-GAAP EPS 93c, consensus 91c
Reports Q4 revenue $10.22B, consensus $10.35B.
February 2, 2016
14:32 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
13:54 EDTMRKMerck technical comments ahead of earnings news
Subscribe for More Information
13:35 EDTMRK, BMYEarnings Watch: Merck down over 5% since last earnings report
Subscribe for More Information
09:46 EDTBMYIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
08:53 EDTBMYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:24 EDTMRKSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
06:44 EDTMRKMerck volatility elevated into Q4 and outlook
Subscribe for More Information
February 1, 2016
06:58 EDTBMYPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTBMYBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use